‘Glimmer of Hope’ Seen for Remdesivir Trials

WASHINGTON (AP) -
Empty vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir are washed at a Gilead Sciences facility in La Verne, California. (Gilead Sciences Inc/Handout via Reuters)

The Emory University medical school doctor leading the remdesivir drug trials said on Thursday that the drug provides a “glimmer of hope” for coronavirus treatment.

Aneesh Mehta told the ABC that “we are looking to find a medication that helps patients get better more rapidly, get them home to their families and make more room for other patients for us to take care of.”

He added: “I think now we have the first glimmer of hope of something that can do that.”

Mehta cautioned that the remdesivir data is “very preliminary.” He says most antivirals tend to work better earlier in the course of disease.

He added that his team is working with the National Institutes of Health to adapt the clinical trial to look at other medications in combination with remdesivir.